Ask AI

Gastrointestinal Cancers

Share

Program Content

Activities

  • ANCHOR
    ANCHOR: Phase III Trial of Anlotinib or Bevacizumab With 1L Chemotherapy for RAS/BRAF Wild-Type Unresectable mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • ATOMIC
    ATOMIC: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab in Patients With Stage III Deficient DNA Mismatch Repair Colon Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • BREAKWATER
    BREAKWATER: PFS From the Phase III Trial of 1L Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • MATTERHORN
    MATTERHORN: Phase III Trial of Durvalumab or Placebo + FLOT in Resectable Gastric and Gastroesophageal Junction Cancers
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • DESTINY Gastric04
    DESTINY-Gastric04: T-DXd vs Ramucirumab + Paclitaxel as Second-line Therapy in HER2+ Unresectable/Metastatic Gastric Cancer/GEJ Adenocarcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • DYNAMIC III
    DYNAMIC-III: ctDNA-Guided Escalation of Adjuvant Chemotherapy vs Standard Management in Stage III Colon Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • CheckMate 577 OS
    CheckMate 577: Final OS Analysis of Adjuvant Nivolumab vs Placebo in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • CodeBreaK 101 Cohort G
    CodeBreaK 101 Cohort G: Sotorasib + Panitumumab and FOLFIRI in Previously Treated KRAS G12C–Mutated mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group